MedTrace Logo

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

NCT02440685 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2023-06-07

Study results available
· View outcomes & findings →

Summary

This study is a dose escalation, and cohort expansion study in subjects with advanced cancer for which no standard therapy exists. Subjects must have received prior treatment for cancer that has not worked, or has stopped working.

Conditions

  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Mantle-Cell
  • Lymphoma, Follicular
  • Cancer
  • Neoplasm
  • Tumor
  • Lymphoma, Malignant
  • Lymphoma, B-cell
  • Lymphoma, Non-Hodgkin
  • B-Cell Chronic Lymphocytic Leukemia
  • B-Cell Leukemia, Chronic
  • B-Lymphocytic Leukemia, Chronic
  • Chronic Lymphocytic Leukemia
  • Leukemia, Lymphocytic, Chronic
  • Leukemia, Lymphocytic, Chronic, B Cell
  • Myelofibrosis
  • Chronic Idiopathic Myelofibrosis
  • Idiopathic Myelofibrosis
  • Lymphoma, T Cell, Peripheral
  • Peripheral T-Cell Lymphoma
  • T-Cell Lymphoma, Peripheral

Interventions

DRUG

ASN002 Dose Escalation

Multiple ascending doses of ASN002 assigned by cohort

DRUG

ASN002 RD

Recommended dose of ASN002 from Part A

Sponsors & Collaborators

  • Asana BioSciences

    lead INDUSTRY

Principal Investigators

  • Niranjan Rao, PhD · Asana BioSciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-06-30
Completion
2018-07-31
FDA Drug
Yes

Countries

  • United States
  • Argentina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02440685 on ClinicalTrials.gov